JP2018514565A5 - - Google Patents

Download PDF

Info

Publication number
JP2018514565A5
JP2018514565A5 JP2017556902A JP2017556902A JP2018514565A5 JP 2018514565 A5 JP2018514565 A5 JP 2018514565A5 JP 2017556902 A JP2017556902 A JP 2017556902A JP 2017556902 A JP2017556902 A JP 2017556902A JP 2018514565 A5 JP2018514565 A5 JP 2018514565A5
Authority
JP
Japan
Prior art keywords
depot
vaccine
seq
forming
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017556902A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018514565A (ja
JP6851983B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2016/050487 external-priority patent/WO2016176761A1/en
Publication of JP2018514565A publication Critical patent/JP2018514565A/ja
Publication of JP2018514565A5 publication Critical patent/JP2018514565A5/ja
Application granted granted Critical
Publication of JP6851983B2 publication Critical patent/JP6851983B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017556902A 2015-05-01 2016-04-27 デポー形成及びデポー非形成ワクチンを使用して免疫応答を強化する方法 Expired - Fee Related JP6851983B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562155677P 2015-05-01 2015-05-01
US62/155,677 2015-05-01
PCT/CA2016/050487 WO2016176761A1 (en) 2015-05-01 2016-04-27 Methods for potentiating an immune response using depot-forming and non-depot-forming vaccines

Publications (3)

Publication Number Publication Date
JP2018514565A JP2018514565A (ja) 2018-06-07
JP2018514565A5 true JP2018514565A5 (enExample) 2019-05-23
JP6851983B2 JP6851983B2 (ja) 2021-03-31

Family

ID=57217405

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017556902A Expired - Fee Related JP6851983B2 (ja) 2015-05-01 2016-04-27 デポー形成及びデポー非形成ワクチンを使用して免疫応答を強化する方法

Country Status (4)

Country Link
US (1) US20180162913A1 (enExample)
EP (1) EP3288538A4 (enExample)
JP (1) JP6851983B2 (enExample)
WO (1) WO2016176761A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016109880A1 (en) 2015-01-06 2016-07-14 Immunovaccine Technologies Inc. Lipid a mimics, methods of preparation, and uses thereof
EP3364949A4 (en) 2015-10-22 2019-07-31 ModernaTX, Inc. CANCER VACCINES
CN109328070A (zh) 2016-05-04 2019-02-12 免疫疫苗技术有限公司 包含两亲化合物、新抗原和疏水载体的疫苗组合物及其使用方法
KR102543118B1 (ko) 2016-05-27 2023-06-14 아게누스 인코포레이티드 항-tim-3 항체 및 이의 사용 방법
JP7125197B2 (ja) 2016-09-27 2022-08-24 イミューノヴァクシーン テクノロジーズ インコーポレイテッド ヒト対象において抗体免疫応答を誘導するために低投与体積ｂ細胞エピトープ組成物を使用する方法
MA47515A (fr) * 2017-02-16 2019-12-25 Modernatx Inc Compositions immunogènes très puissantes
CN109456405B (zh) * 2017-09-06 2022-02-08 上海交通大学医学院附属仁济医院 一种去棕榈酰化pd-l1蛋白质及其制备方法和应用
WO2019090411A1 (en) * 2017-11-09 2019-05-16 Immmunovaccine Technologies Inc. Pharmaceutical compositions, methods for preparation comprising sizing of lipid vesicle particles, and uses thereof
CN107988373A (zh) * 2018-01-10 2018-05-04 上海交通大学医学院附属仁济医院 用于预测癌症免疫治疗效果的生物标志物、试剂盒与应用
EP3768242A4 (en) * 2018-03-20 2021-12-08 ImmunoVaccine Technologies Inc. METHODS AND COMPOSITIONS FOR THE TARGETED DELIVERY OF ACTIVE SUBSTANCES AND IMMUNMODULATORY AGENTS TO LYMPH NODES
CN113329761A (zh) 2018-09-04 2021-08-31 特雷斯生物有限公司 肽疫苗
CA3119910A1 (en) * 2018-11-19 2020-05-28 Immunovaccine Technologies Inc. Methods for improving the efficacy of a survivin therapeutic in the treatment of tumors
WO2024186623A1 (en) 2023-03-03 2024-09-12 BioVaxys Inc. Methods of making dried pharmaceutical compositions
WO2024186646A1 (en) 2023-03-03 2024-09-12 BioVaxys Inc. Methods of making lipid adjuvanted compositions

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7892559B2 (en) * 2002-01-30 2011-02-22 Survac Aps Survivin-derived peptides and use thereof
US7601801B2 (en) * 2003-07-11 2009-10-13 Dainippon Sumitomo Pharma Co., Ltd. HLA-A24 binding cancer antigen peptide derived from livin
US7749520B2 (en) * 2004-07-07 2010-07-06 Statens Serum Institut Compositions and methods for stabilizing lipid based adjuvant formulations using glycolipids
KR20070101341A (ko) * 2005-02-01 2007-10-16 메디바스, 엘엘씨 백신 전달 조성물 및 사용 방법
US7947286B2 (en) * 2005-10-07 2011-05-24 Panthera Biopharma Llc Drosophila cell lines producing recombinant secretable filovirus surface glycoproteins lacking the membrane spanning domain
CA2523032A1 (en) * 2005-10-07 2007-04-07 Immunovaccine Technologies Inc. Vaccines for cancer therapy
US20090092635A1 (en) * 2007-08-17 2009-04-09 Wyeth Heterologous prime-boost immunization regimen
US20100209452A1 (en) * 2007-10-03 2010-08-19 Immunovaccine Technologies, Inc Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof
CA2723918C (en) * 2008-06-05 2018-01-09 Immunovaccine Technologies Inc. Compositions comprising liposomes, an antigen, a polynucleotide and a carrier comprising a continuous phase of a hydrophobic substance
CN103118709A (zh) * 2010-03-26 2013-05-22 新兴产品开发盖瑟斯堡有限公司 流感病毒基质2蛋白的胞外域、其表达系统和应用
WO2014055289A1 (en) * 2012-10-01 2014-04-10 Thomas Jefferson University Immunization with rabies virus vector expressing foreign protein antigen
WO2014153636A1 (en) * 2013-03-27 2014-10-02 Immunovaccine Technologies Inc. Method for improving the efficacy of a survivin vaccine in the treatment of cancer

Similar Documents

Publication Publication Date Title
Petkar et al. An overview of nanocarrier-based adjuvants for vaccine delivery
Chatzikleanthous et al. Lipid-based nanoparticles for delivery of vaccine adjuvants and antigens: toward multicomponent vaccines
Yang et al. Recent advances in the development of toll-like receptor agonist-based vaccine adjuvants for infectious diseases
Moni et al. Advancements in vaccine adjuvants: the journey from alum to nano formulations
Gote et al. A comprehensive review of mRNA vaccines
Facciolà et al. An overview of vaccine adjuvants: current evidence and future perspectives
Tan et al. Outer membrane vesicles: current status and future direction of these novel vaccine adjuvants
Tornesello et al. Nanoparticles to improve the efficacy of peptide-based cancer vaccines
TWI672149B (zh) 改良之疫苗組成物及使用方法
Goetz et al. Vaccine adjuvants for infectious disease in the clinic
Gomes et al. Harnessing nanoparticles for immunomodulation and vaccines
Cunningham et al. Vaccine development: From concept to early clinical testing
Martiñón et al. Chemical and immunological characteristics of aluminum‐based, oil‐water emulsion, and bacterial‐origin adjuvants
JP2015522580A5 (enExample)
Barnier-Quer et al. Adjuvant effect of cationic liposomes for subunit influenza vaccine: influence of antigen loading method, cholesterol and immune modulators
Jabbal-Gill Nasal vaccine innovation
JP2014520807A5 (enExample)
JP2018534304A5 (enExample)
Levast et al. Vaccine potentiation by combination adjuvants
Atmar et al. Adjuvants for pandemic influenza vaccines
JP2014522842A5 (enExample)
CN103768595B (zh) 唑来膦酸佐剂及含唑来膦酸佐剂的疫苗
RU2009144125A (ru) Виросомы, содержащие гемагглютинин, полученный из вируса гриппа, вырабатываемого в клеточной линии; композиции, методы получения и применение на их основе
JP2013181034A5 (enExample)
JP2000507921A (ja) ポリ（アミドアミン）デンドリマーのアジュバント性